| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b5dd388a5130b0bdede0fdfc6c2af6ed |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5047
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C40B30-00 |
| filingDate |
2008-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_06a01d26af04561ddd7141a68755e877
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a874dd87b7b373e57a4d2fba3a5e6ee2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_34e1e05b56c24398d99d36e1dd000582
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1b671bba2569546c3c404deaa3daf784 |
| publicationDate |
2009-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2643886-A1 |
| titleOfInvention |
Selection of personalized cancer therapy regimens using interfering rna functional screening |
| abstract |
Methods for screening cells obtained from a subject for aberrant kinase activity are disclosed. The methods include placing cells isolated from the subject in contact with a set of siRNAs, wherein each individual siRNA is at an addressable location on the array and specifically inhibits expression of a tyrosine kinase. The siRNA is introduced into the blood cells or bone marrow cells by electroporation. After introduction of the siRNA, the cells are then assayed for proliferation and/or viability as compared to a control. A decreased proliferation and/or viability of the cells as compared to a control identifies a siRNA that inhibits the proliferation and/or viability of the cells, thus identifying the tyrosine kinase having aberrant tyrosine kinase activity in the subject. |
| priorityDate |
2008-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |